Background. Nebivolol is a highly selective β1-adrenoreceptor antagonist with vasodilating
properties. This study investigated its effect on quality of life (QoL) and blood pressure (BP) …

Background: An experimental study showed that nebivolol is an effective agent in contrast‐
induced nephropathy (CIN) prophylaxis. Hypothesis: We hypothesized that prophylactic …

Introduction Cardiovascular diseases are the main cause of mortality worldwide, and
systemic arterial hypertension is associated with a large number of these cases. The …

Abstract Introduction: Hypertension,“The silent killer” is a multifactorial disorder which is
asymptomatic and if left untreated leads to lethal complications. Nebivolol is a third …

Abstract β-Adrenergic receptor blockers (β-blockers) are well-known useful and cost-
effective drugs for managing hypertensive patients with coronary heart disease, stroke, and …

Background: Coronary artery disease (CAD) is one of the leading causes of mortality and
morbidity in India. Oxidative stress and endothelial dysfunction play a major role in the …

β-blockers have been widely used for the treatment of hypertension, congestive heart failure
and angina, as well as in the post-myocardial infarction population. Both β1 selective and …

Nebivolol is a cardioselective lipophilic β-blocker devoid of intrinsic sympathomimetic and
membrane-stabilizing actions. The pharmacological profile differs from that of conventional …

Nebivolol is a recently developed β-blocker provided with vasodilator properties. Because
the mechanism of the putative endothelium-dependent effect of this β-adrenoceptor blocker …

Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …